Add to ORKGThere is a worldwide rapid increase in the prevalence of type 2 diabetes, due to factors such as improved affluence, longevity, and obesity. To prevent the development of diabetes, individuals must be identified at an early stage of risk and targeted with preventive measures such as lifestyle advice and pharmacological therapy. A key indicator of risk is impaired glucose tolerance. We have recently begun the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial to gather epidemiological data and provide insight into the protective effects of the angiotensin receptor blocker valsartan in patients with improved glucose intolerance
OBJECTIVE Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Tr...
BACKGROUND The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardi...
OBJECTIVE Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Tr...
There is a worldwide rapid increase in the prevalence of type 2 diabetes, due to factors such as imp...
Patients with impaired glucose tolerance (IGT) have increased risk for developing type 2 diabetes me...
Patients with impaired glucose tolerance (IGT) have increased risk for developing type 2 diabetes me...
Valsartan reduced diabetes but not CV events in patients with impaired glucose tolerance and CV risk...
The Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial is expl...
Objective: To examine the degree to which use of β blockers, statins, and diuretics in patients with...
It is well recognised that the metabolic syndrome, a constellation of risk factors including obesity...
BACKGROUND: It is not known whether drugs that block the renin-angiotensin system reduce the risk of...
It is well recognised that the metabolic syndrome, a constellation of risk factors including obesity...
OBJECTIVE Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Tr...
OBJECTIVE Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Tr...
OBJECTIVE Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Tr...
OBJECTIVE Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Tr...
BACKGROUND The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardi...
OBJECTIVE Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Tr...
There is a worldwide rapid increase in the prevalence of type 2 diabetes, due to factors such as imp...
Patients with impaired glucose tolerance (IGT) have increased risk for developing type 2 diabetes me...
Patients with impaired glucose tolerance (IGT) have increased risk for developing type 2 diabetes me...
Valsartan reduced diabetes but not CV events in patients with impaired glucose tolerance and CV risk...
The Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial is expl...
Objective: To examine the degree to which use of β blockers, statins, and diuretics in patients with...
It is well recognised that the metabolic syndrome, a constellation of risk factors including obesity...
BACKGROUND: It is not known whether drugs that block the renin-angiotensin system reduce the risk of...
It is well recognised that the metabolic syndrome, a constellation of risk factors including obesity...
OBJECTIVE Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Tr...
OBJECTIVE Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Tr...
OBJECTIVE Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Tr...
OBJECTIVE Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Tr...
BACKGROUND The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardi...
OBJECTIVE Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Tr...